TRO and liver cancer: In this study, we provide the first direct evidence for the presence of KIAA1114 at the protein level in cancer cells by utilizing a monoclonal antibody (mAb) raised against the extracellular domain of KIAA1114 antigen and propose its potential role as a prognostic factor, and more significantly, as a distinctive and versatile TIC surface marker for multiple subtypes of human liver cancer.